[177Lu]Lu-DOTA-EB-RGD2 Therapy in Patients With Recurrent High-grade Glioma
An Investigator-Initiated Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Efficacy of [177Lu]Lu-DOTA-EB-RGD2 in Patients With Recurrent High-grade Glioma
研究概览
详细说明
This is a multicenter, open-label, Phase I dose-escalation study with two parallel routes of administration: intravenous (IV) and locoregional (via Ommaya reservoir into the tumor cavity). The primary objective is to determine the maximum tolerated dose (MTD) of [177Lu]Lu-DOTA-EB-RGD2 for each route using a standard "3+3" design. Three dose levels per cycle are planned for each route (IV and locoregional). Treatment is given every 3 weeks for up to 2 cycles, with possible additional cycles based on clinical benefit as judged by the investigator.
Primary endpoint: Dose-limiting toxicity (DLT) incidence during the first 6 weeks (2 cycles), graded by CTCAE v5.0.
Secondary endpoints: Adverse events (type, frequency, severity); time-activity curves and absorbed radiation doses in organs and tumors (based on whole-body planar imaging and SPECT/CT at multiple time points); pharmacokinetic parameters (AUC, Cmax, Tmax, clearance [CL], volume of distribution [Vz], terminal half-life) from blood and urine sampling; objective response rate (ORR) per RANO 2.0 (by contrast-enhanced MRI); overall survival.
Exploratory endpoints: Change in tumor αvβ3 integrin expression by NOTA-PRGD2 PET/CT; correlation between baseline NOTA-PRGD2 PET uptake and treatment response.
Sample size: Approximately 24 patients (up to 3+3 per dose level per route) using the 3+3 rule. No formal hypothesis testing is planned; descriptive statistics will be used.
Study duration: 36 months (recruitment approximately 12 months, treatment and follow-up approximately 24 months). The trial is conducted at Beijing Tiantan Hospital and Peking Union Medical College Hospital, China.
研究类型
注册 (估计的)
阶段
- 第一阶段早期
联系人和位置
学习联系方式
- 姓名:Li'ao Wang, M.D.
- 电话号码:+86 15001171671
- 邮箱:wangliao17@163.com
研究联系人备份
- 姓名:Deling Li, M.D.
- 邮箱:lideling@bjtth.org
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国、100070
- 招聘中
- Beijing Tiantan Hospital, Capital Medical University
-
首席研究员:
- Deling Li, M.D.
-
接触:
- Li'ao Wang, M.D.
- 电话号码:15001171671
- 邮箱:wangliao17@163.com
-
Beijing、Beijing Municipality、中国、100730
- 招聘中
- Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
-
接触:
- Zhaohui Zhu, M.D.
- 电话号码:+86 15909835868
- 邮箱:13611093752@163.com
-
首席研究员:
- Zhaohui Zhu, M.D.
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- The participant must sign the informed consent form before participation.
- Age ≥ 18 years.
- Histologically confirmed glioblastoma (WHO classification) after surgical resection or biopsy.
- Participants receiving corticosteroids (e.g., dexamethasone) must be on a stable or decreasing dose ≤ 4 mg/day (or equivalent) for at least 7 days before start of study treatment.
Adequate bone marrow and organ function confirmed by laboratory tests performed ≤ 14 days before first study treatment:
Absolute neutrophil count (ANC) ≥ 1.5 × 10⁹/L; Platelet count ≥ 100 × 10⁹/L; Hemoglobin ≥ 10.0 g/dL; Serum creatinine ≤ 1.5 × upper limit of normal (ULN); Total bilirubin ≤ 1.5 × ULN; albumin ≥ 30 g/L; ALT and AST < 3 × ULN in absence of liver metastases, or < 5 × ULN if liver metastases present; Coagulation: activated partial thromboplastin time (APTT) ≤ 2 × ULN, international normalized ratio (INR) ≤ 1.5 (if not receiving anticoagulation therapy);
- Evidence of disease progression (PD) by RANO 2.0 criteria confirming recurrence: ≥ 25% increase in product of perpendicular diameters or > 40% increase in tumor volume compared to baseline after initial treatment or best response, while on stable or increasing corticosteroid dose. Clinical deterioration or increased corticosteroid dose alone is insufficient. MRI contrast enhancement, MRS, and/or metabolic PET should help differentiate true progression from radiation necrosis/pseudoprogression. Also, at least one bi-dimensionally measurable contrast-enhancing lesion with shortest diameter ≥ 10 mm must be present on MRI.
- For participants receiving Ommaya reservoir implantation for locoregional administration, surgery must be completed at least 2 weeks before first radionuclide therapy, with no postoperative complications. Baseline MRI for efficacy assessment must be performed at least 2 weeks after implantation and before first radionuclide therapy.
- Tumor uptake confirmed by NOTA-PRGD2 PET/CT after diagnosis of recurrence and before radionuclide therapy. For participants with Ommaya reservoir, PET/CT must be performed at least 2 weeks after implantation and before first radionuclide therapy.
- Life expectancy > 6 months.
- Karnofsky Performance Status (KPS) score ≥ 50.
Exclusion Criteria:
- Receiving any other concurrent treatment for glioblastoma outside this study.
- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed from the start of [177Lu]Lu-DOTA-EB-RGD2 treatment until 6 months after treatment.
- Refusal to use effective contraception during sexual intercourse from informed consent until 6 months after the last dose of study drug.
- Inability to tolerate imaging procedures, repeated blood sampling, or poor venous access.
- Cardiac dysfunction, clinically significant cardiac disease history, or ECG abnormalities indicating a major safety risk, including:
(1) Documented myocardial infarction, angina pectoris, cardiomyopathy, symptomatic pericarditis, or coronary artery bypass grafting within 6 months before enrollment.
(2) Long QT syndrome, family history of idiopathic sudden death or congenital long QT syndrome, or any of the following: (a) risk factors for torsade de pointes (TdP) including uncorrected hypocalcemia, hypokalemia, hypomagnesemia, history of heart failure, or clinically significant/symptomatic bradycardia; (b) use of medications known to prolong the QT interval and/or cause TdP that cannot be discontinued or replaced with a safer alternative (e.g., within 5 half-lives or 7 days before study drug); (c) inability to determine the Fridericia-corrected QT interval (QTcF).
(3) Clinically significant arrhythmia (e.g., ventricular tachycardia), complete left bundle branch block, high-grade atrioventricular block (e.g., bifascicular block, Mobitz type II, third-degree AV block).
(4) Resting QTcF ≥ 450 ms (male) or ≥ 460 ms (female). (5) Left ventricular ejection fraction (LVEF) < 50% by echocardiography. (6) Uncontrolled hypertension defined as systolic blood pressure ≥ 160 mmHg and/or diastolic blood pressure ≥ 100 mmHg, regardless of antihypertensive use.
6. Other malignancy within 5 years before study drug administration, except adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer after curative surgery, carcinoma in situ after curative surgery, or papillary thyroid cancer after curative surgery (hormonal therapy for non-metastatic prostate or breast cancer allowed).
7. Abnormal serum virology (HBsAg, T. pallidum antibody, HIV antibody, HCV antibody). Patients with untreated active hepatitis B who are willing to receive anti-HBV therapy during study treatment are allowed; patients with inactive hepatitis B are allowed; patients with inactive hepatitis C (HCV antibody positive but HCV RNA below lower limit of detection) are allowed.
8. Use of bevacizumab for glioblastoma or supportive care (e.g., edema reduction) within 60 days before start of study treatment.
9. Patients with disease progression within the first 12 weeks after completion of radiotherapy are excluded from recurrent disease trials.
10. Prior intracranial locoregional drug therapy before [177Lu]Lu-DOTA-EB-RGD2 treatment.
11. Active intracranial or intratumoral hemorrhage detected by CT/MRI. 12. Seizure within 14 days before start of study treatment; epilepsy or increased intracranial pressure uncontrolled by medication.
13. Grade 4 myelosuppression from prior anticancer therapy that has not recovered within 2 weeks, or grade 3 myelosuppression requiring >6 weeks to recover.
14. Blood transfusion within 4 weeks before screening to meet eligibility criteria.
15. Known hypersensitivity or delayed allergic reaction to any component of [177Lu]Lu-DOTA-EB-RGD2 or similar drugs.
16. Severe disease of the cardiac, respiratory, central nervous system, renal, hepatic, or other organ systems that, in the investigator's opinion, may increase participant safety risk.
17. Active infection requiring intravenous antibiotics (bacterial, fungal, or viral) within 4 weeks before first dose, or any other uncontrolled active infection deemed clinically significant by the investigator.
18. History of drug or alcohol abuse within one year before screening, long-term drug use, or psychiatric illness that may affect compliance.
19. Participation in another investigational drug or device trial within 4 weeks before first dose.
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:非随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Intravenous Administration of [177Lu]Lu-DOTA-EB-RGD2
Participants receive [177Lu]Lu-DOTA-EB-RGD2 via intravenous infusion 20-30 minutes once every 3 weeks (Q3W) for up to 2 cycles (6 weeks).
Dose escalation follows a 3+3 design with three dose levels per cycle.
Additional cycles may be given based on clinical benefit.
|
A long-circulating radiolabeled peptide targeting integrin αvβ3.
The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days).
It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity.
The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.
|
|
实验性的:Locoregional Administration of [177Lu]Lu-DOTA-EB-RGD2
Participants receive [177Lu]Lu-DOTA-EB-RGD2 directly into the tumor cavity through a previously implanted Ommaya reservoir once every 3 weeks (Q3W) for up to 2 cycles (6 weeks).
Dose escalation follows a 3+3 design with three dose levels per cycle.
Additional cycles may be given based on clinical benefit.
|
A long-circulating radiolabeled peptide targeting integrin αvβ3.
The radiopharmaceutical consists of an RGD2 peptide conjugated to a DOTA chelator and an albumin-binding (EB) motif, labeled with Lutetium-177 (half-life 6.7 days).
It is administered intravenously (20-30 min infusion) or locoregionally via Ommaya reservoir directly into the tumor cavity.
The study evaluates safety, tolerability, dosimetry, and preliminary efficacy in recurrent high-grade glioma.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
大体时间:Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)
|
DLTs are defined as protocol-specified adverse events occurring during the first 6 weeks (2 cycles) after the first dose, graded by NCI CTCAE v5.0. DLTs include: Grade ≥3 neurological toxicities (e.g., grade 3 CNS necrosis, grade 3 decreased consciousness, grade 3 hydrocephalus, grade 3 seizure, grade 3 headache that lasts over 24 hours with treatments, grade ≥4 cerebral edema); Grade ≥3 hematologic toxicities (e.g., grade 3 febrile neutropenia, grade 3 anemia lasting >7 days, grade 3 lymphopenia with infection, grade 4 neutropenia lasting >7 days, grade 4 thrombocytopenia or grade 3 with bleeding); Any grade ≥3 non-hematologic toxicity (except transient grade 3 nausea/vomiting/diarrhea lasting <3 days, grade 3 fatigue lasting <1 week, or electrolyte abnormality lasting less than 72 hours and resolved by supportive care); Any Hy's law event (e.g., ALT or AST > 3-fold upper limit normal); Death or significant clinical intervention related to the study drug. |
Within 6 weeks (42 days) after the first dose (during the first two cycles; each cycle is 21 days)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence and severity of adverse events (AEs)
大体时间:From the first dose (Day 1) until study completion (up to 17 months)
|
All adverse events (AEs), serious AEs (SAEs), treatment-emergent AEs (TEAEs), and deaths, graded by NCI CTCAE v5.0.
Assessment includes changes in vital signs, physical examination, electrocardiogram (ECG), echocardiogram (for participants >60 years), laboratory tests (hematology, serum chemistry, coagulation, urinalysis), and serum pregnancy test (for females of childbearing potential).
AE resolution or progression is tracked throughout follow-up.
|
From the first dose (Day 1) until study completion (up to 17 months)
|
|
Radiation Dosimetry
大体时间:From the first dose up to 192 hours (Day 8)
|
Time-activity curves (TACs) derived from whole-body planar imaging and SPECT/CT at multiple time points post-injection.
Absorbed doses to the tumor and major organs are calculated using the MIRD methodology.
|
From the first dose up to 192 hours (Day 8)
|
|
Maximum Tolerated Dose (MTD)
大体时间:Within 6 weeks (42 days) after the first dose
|
The highest dose level at which ≤1 of 6 participants experiences a DLT during the first 6 weeks (2 cycles), determined separately for the intravenous and locoregional administration arms using the 3+3 dose-escalation design.
|
Within 6 weeks (42 days) after the first dose
|
|
Area Under the Concentration-Time Curve (AUC) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
大体时间:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
AUC calculated from time zero to last measurable time point and/or to infinity, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Objective Response Rate (ORR)
大体时间:Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)
|
Proportion of participants achieving complete response (CR) or partial response (PR) on contrast-enhanced MRI according to RANO 2.0 criteria.
CR is defined as disappearance of all enhancing and non-enhancing lesions without new lesions; PR is defined as a ≥50% decrease in the product of perpendicular diameters from baseline.
|
Baseline, Day 22 (±3 days), Day 42 (±7 days), then every 6 weeks until progression, death, or start of new therapy (up to 17 months)
|
|
Overall Survival (OS)
大体时间:From the first dose up to 17 months (study duration)
|
Time from the first dose of [177Lu]Lu-DOTA-EB-RGD2 to death from any cause.
Participants alive at study end or lost to follow-up are censored at their last known alive date.
|
From the first dose up to 17 months (study duration)
|
|
Maximum Plasma Concentration (Cmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
大体时间:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Cmax directly observed from concentration-time data, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Time to Maximum Plasma Concentration (Tmax) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
大体时间:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Tmax corresponding to Cmax, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Systemic Clearance (CL) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
大体时间:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
CL calculated as Dose/AUC, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Volume of Distribution During Terminal Phase (Vz) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
大体时间:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
Vz calculated as CL/λz, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
|
Terminal Half-Life (t1/2) of [177Lu]Lu-DOTA-EB-RGD2 in Blood
大体时间:Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
t1/2 calculated from the terminal phase of the concentration-time curve, measured from venous blood samples.
|
Pre-dose; 5, 15, 30, 60 minutes; 2, 4, 24, 48, 72, 144, 192 hours post-dose (first cycle only; each cycle is 21 days)
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in Tumor Uptake of NOTA-PRGD2 on PET/CT
大体时间:Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose
|
Changes in tumor SUVmax, SUVmean, and tumor-to-background ratio (TBR) from baseline to post-treatment PET/CT scans, as an exploratory biomarker of target engagement.
|
Baseline (within 42 days before the first dose) and Day 42 (±7 days) after the first dose
|
合作者和调查者
调查人员
- 首席研究员:Deling Li, M.D.、Beijing Tiantan Hospital
- 首席研究员:Zhaohui Zhu、Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他研究编号
- BRWEP2024W032040206
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.